(Sharecast News) - AIM-listed Genedrive said on Friday that shareholder David Nugent had shown "willingness" to make a cash injection into the point-of-care pharmacogenetic testing company.
The company said that since its general meeting on 15 October, it has "continued to engage constructively" with Nugent - who has a 16% interest...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE